Topical Tobramycin via Nasal Nebulization: New Clinical Test Demonstrates Low Serum Absorption

Serum peak & trough levels were drawn after four days of inhalation therapy at the 12th dose and revealed an average peak of 0.3 mcg /ml and an average trough of less than 0.1 mcg/ml. (In IV cases tobramycin levels would be managed to below 2.0 mcg /ml.) Ninety percent of patients reported being "better" after completing their course of therapy. No patients reported adverse side effects such as dizziness or tinnitus. Conclusion: These results further support the use of topical tobramycin as a safe method of medication administration via nasal nebulization for pseudomonas sinus infections. height:; border-top:solid; border-bottom:solid; border-right: none; border-left:none; border-width: 0px; border-color:#FFF; background:#FFF; color:#748DA7; font-size: 16px; font-family: Arial, Helvetica, sans-serif; font-weight: bold’>